Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AMJEVITA vs ERELZI
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Adalimumab is a recombinant human Ig G1 monoclonal antibody that binds specifically to tumor necrosis factor-alpha (TNF-α) and blocks its interaction with p55 and p75 cell surface TNF receptors. It also modulates biological responses that are induced or regulated by TNF-α, including expression of adhesion molecules, chemotaxis, and pro-inflammatory cytokine release.
Erelzi (etanercept-szzs) is a tumor necrosis factor (TNF) blocker. It is a dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) TNF receptor linked to the Fc portion of human Ig G1. Erelzi binds specifically to TNF-alpha and blocks its interaction with cell surface TNF receptors, thereby reducing TNF-mediated inflammatory responses.
Rheumatoid arthritis (moderate to severe active, alone or with methotrexate),Juvenile idiopathic arthritis (moderate to active polyarticular, age ≥2 years),Psoriatic arthritis (active, alone or with DMARDs),Ankylosing spondylitis (active),Crohn's disease (moderate to severe, age ≥6 years),Ulcerative colitis (moderate to severe, adults),Plaque psoriasis (moderate to severe chronic, adults),Hidradenitis suppurativa (moderate to severe, adults),Uveitis (non-infectious intermediate, posterior, and panuveitis, adults and children ≥2 years)
Rheumatoid arthritis (moderately to severely active),Polyarticular juvenile idiopathic arthritis (moderate to severe),Psoriatic arthritis,Ankylosing spondylitis,Plaque psoriasis (chronic moderate to severe)
Subcutaneous injection: 40 mg every other week; for patients with Crohn disease, an initial dose of 160 mg (given as four 40 mg injections in one day or two 40 mg injections per day for two consecutive days) followed by 80 mg at week 2 and 40 mg every other week starting at week 4.
For plaque psoriasis: 100 mg subcutaneous injection once weekly, after initial loading dose of 200 mg at weeks 0, 1, 2, 3, and 4. For psoriatic arthritis: 100 mg subcutaneous injection once weekly.
Terminal elimination half-life is approximately 14 days (range 10-20 days) in patients receiving 40 mg every other week. This long half-life supports biweekly dosing.
Terminal elimination half-life: 13–16 days (mean 14.6 days) in adults with moderate-to-severe plaque psoriasis; clinical context: supports every-2-week subcutaneous dosing regimen.
Adalimumab is a monoclonal antibody; it is not metabolized by cytochrome P450 enzymes. Clearance occurs via catabolism to small peptides and amino acids.
Erelzi is a monoclonal antibody-based fusion protein. It is expected to be degraded into small peptides and amino acids via general protein catabolism. No specific metabolic pathways or enzymes have been identified; it is not metabolized by cytochrome P450 enzymes.
Adalimumab (AMJEVITA) is eliminated primarily via intracellular catabolism, with negligible renal or biliary excretion. No intact drug is excreted in urine. The Fe receptor-mediated recycling contributes to long half-life.
Renal: negligible (not significantly excreted unchanged); Biliary/Fecal: primary elimination pathway via proteolytic catabolism to amino acids; approximately 95% of dose recovered as small peptides/amino acids in feces.
Adalimumab is a monoclonal antibody; protein binding is negligible as it is not bound to serum proteins. However, it may bind to soluble TNF-alpha with high affinity.
Approximately 95–98% bound; primarily to endogenous immunoglobulins (Ig G) via Fc Rn binding; minimal binding to albumin or other plasma proteins.
Volume of distribution (Vd) is approximately 4.7-6.0 L (0.06-0.08 L/kg for a 70 kg adult). This small Vd reflects distribution primarily in the vascular and interstitial spaces, consistent with a large protein.
Volume of distribution: 3.5–4.0 L (approximately 0.05 L/kg for a 70 kg adult), indicating limited extravascular distribution, predominantly confined to vascular space and interstitial fluid.
Subcutaneous bioavailability: 64% (range 50-80%) after 40 mg SC injection. No intravenous formulation is approved; absolute bioavailability determined by comparison to IV administration.
Subcutaneous: absolute bioavailability approximately 75–80% following injection into thigh, abdomen, or upper arm.
No dose adjustment required for any degree of renal impairment.
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (e GFR <30 m L/min/1.73 m²); use with caution.
No dose adjustment required for any degree of hepatic impairment.
No formal studies in hepatic impairment. Use with caution in Child-Pugh Class B or C due to potential altered clearance.
For pediatric patients weighing ≥40 kg: 40 mg subcutaneously every other week; for weight <40 kg: 20 mg subcutaneously every other week.
Safety and efficacy not established in pediatric patients <18 years old; no approved dosing.
No specific dose adjustment recommended; use with caution due to higher risk of infections.
No specific dose adjustment recommended based on age alone; monitor for adverse effects due to potential age-related decreases in renal function.
Increased risk of serious infections leading to hospitalization or death, including tuberculosis (TB), invasive fungal infections, and other opportunistic pathogens. Patients should be tested for latent TB before and during therapy. Malignancies, including lymphoma, have been reported in children and adolescents treated with TNF blockers.
WARNING: SERIOUS INFECTIONS AND MALIGNANCY. Patients treated with TNF blockers, including Erelzi, are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. Discontinue Erelzi if a patient develops a serious infection. Reported infections include: active tuberculosis (including reactivation of latent TB), invasive fungal infections (e.g., histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis), and bacterial, viral, or other opportunistic infections. Lymphoma and other malignancies, some fatal, have been reported in children and adolescents treated with TNF blockers.
Serious infections (bacterial, viral, fungal, including reactivation of HBV),Invasive fungal infections (e.g., histoplasmosis, coccidioidomycosis, candidiasis),Malignancies (lymphoma, leukemia, melanoma, Merkel cell carcinoma, other),Anaphylaxis and allergic reactions,Demyelinating disease (new onset or exacerbation of CNS demyelinating disorders),Hematologic reactions (pancytopenia, aplastic anemia),Congestive heart failure (new onset or worsening),Lupus-like syndrome (autoantibodies, rarely clinical disease),Hepatitis B reactivation,Use with abatacept or anakinra (increased risk of infection)
Serious infections: Do not start Erelzi in patients with active infections. Monitor for signs/symptoms of infection during treatment.,Malignancies: Risk of lymphoma and other malignancies; higher in children and adolescents.,Hepatitis B reactivation: Screen for HBV before starting therapy; discontinue if reactivation occurs.,Demyelinating disorders: Rare cases of CNS demyelinating disorders (e.g., multiple sclerosis, optic neuritis) reported; use caution in patients with pre-existing or recent-onset demyelinating disorders.,Congestive heart failure: Use caution in patients with heart failure; discontinue if new or worsening symptoms occur.,Hematologic events: Pancytopenia, aplastic anemia reported; advise patients to seek medical attention if signs of blood dyscrasias develop.,Hypersensitivity: Serious allergic reactions (including anaphylaxis) have been reported; discontinue if reaction occurs.,Immunizations: Avoid live vaccines during therapy.
Known hypersensitivity to adalimumab or any component of the formulation,Active serious infection including sepsis
Severe infections including sepsis,Known hypersensitivity to etanercept or any component of the product
No specific food interactions. No dietary restrictions required.
No known food interactions. Grapefruit and other foods do not affect bimekizumab. However, maintain a balanced diet. If you have a history of liver disease, follow any dietary recommendations provided by your healthcare provider, but there are no specific restrictions.
Amjevita (adalimumab) is an Ig G1 monoclonal antibody that crosses the placenta during the third trimester, with highest fetal exposure in the third trimester. In the first and second trimesters, placental transfer is limited. Available data from the OTIS autoimmune diseases in pregnancy study and other cohort studies do not indicate a substantially increased risk of major birth defects or miscarriage with adalimumab exposure during pregnancy. However, there is a potential risk of immunosuppression in the neonate, including increased risk of infections, if the mother is exposed during the second and third trimesters. Infants should not be vaccinated with live vaccines for at least 5 months after maternal last dose.
Pregnancy Category N. No adequate animal reproduction studies. No well-controlled human studies. At therapeutic doses, immunomodulatory effects may theoretically increase risk of pregnancy loss and congenital anomalies. First trimester exposure: unknown teratogenic risk. Second and third trimester: potential for adverse fetal immune effects.
Adalimumab is excreted in breast milk in low concentrations. The milk-to-plasma ratio is approximately 0.04. Limited data indicate that infants are exposed to less than 1% of the maternal dose, and no adverse effects have been reported in breastfed infants. Because adalimumab is a large protein, it undergoes proteolysis in the infant's gastrointestinal tract and is not systemically absorbed. Therefore, breastfeeding is considered compatible with adalimumab therapy.
No data on presence in breast milk. M/P ratio unknown. Maternal Ig G is known to be excreted in breast milk; as a monoclonal antibody, Erelzi may be present. Caution recommended, especially in preterm infants or those with compromised gastrointestinal barrier.
During pregnancy, adalimumab clearance may increase, especially in the third trimester, leading to lower trough concentrations. However, no dose adjustment is routinely recommended due to lack of data showing altered clinical outcomes. Therapeutic drug monitoring is not standard, but if disease activity increases, consider modifying the dose or frequency as per non-pregnant guidelines. Postpartum, clearance returns to prepregnancy levels, so doses should be adjusted back to prepregnancy regimen if modified.
No established dose adjustments for pregnancy. Pharmacokinetics of monoclonal antibodies may change due to increased plasma volume and altered metabolism. Consider therapeutic drug monitoring if available, but lack of data precludes specific dose changes.
AMJEVITA (adalimumab-atto) is a biosimilar to Humira. Administer subcutaneously; rotate injection sites. Do not administer live vaccines. Screen for TB and hepatitis B before initiation. Consider withholding for serious infections. Monitor for allergic reactions and blood dyscrasias.
ERELZI (bimekizumab) is a humanized monoclonal Ig G1 antibody that selectively inhibits IL-17A and IL-17F. For plaque psoriasis, consider loading dose: 320 mg (two 160 mg injections) subcutaneously at weeks 0, 4, 8, then 320 mg every 8 weeks. Monitor for hypersensitivity reactions and infections. May elevate liver enzymes; check baseline and periodic LFTs. Avoid live vaccines. Can be used with caution in patients with history of inflammatory bowel disease. Injection site reactions are common; rotate sites. Not recommended in pregnancy unless benefit outweighs risk.
Store in refrigerator, do not freeze; protect from light.,Inject at room temperature; allow to sit out 15-30 minutes.,Rotate injection sites; avoid tender, bruised, or scarred skin.,Report signs of infection (fever, chills, cough) or allergic reaction immediately.,Do not receive live vaccines while on this medication.,Inform all healthcare providers of your use of AMJEVITA.
ERELZI is given as an injection just under the skin; you or a caregiver can be trained to inject at home.,Store in refrigerator at 36°F to 46°F (2°C to 8°C); do not freeze. Protect from light. Let it sit at room temperature for 30 minutes before injecting.,Do not use if solution is cloudy, discolored, or contains particles.,Tell your doctor if you have any signs of infection (fever, chills, cough, painful urination) or allergic reaction (rash, itching, difficulty breathing).,Avoid live vaccines during treatment.,You may need blood tests to check your liver function before and during treatment.,Seek medical attention if you develop symptoms of inflammatory bowel disease (new or worsening abdominal pain, diarrhea, blood in stool).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AMJEVITA vs ERELZI, answered by our medical review team.
AMJEVITA is a TNF-alpha Inhibitor that works by Adalimumab is a recombinant human Ig G1 monoclonal antibody that binds specifically to tumor necrosis factor-alpha (TNF-α) and blocks its interaction with p55 and p75 cell surface TNF receptors. It also modulates biological responses that are induced or regulated by TNF-α, including expression of adhesion molecules, chemotaxis, and pro-inflammatory cytokine release.. ERELZI is a TNF-alpha Inhibitor that works by Erelzi (etanercept-szzs) is a tumor necrosis factor (TNF) blocker. It is a dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) TNF receptor linked to the Fc portion of human Ig G1. Erelzi binds specifically to TNF-alpha and blocks its interaction with cell surface TNF receptors, thereby reducing TNF-mediated inflammatory responses.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AMJEVITA and ERELZI depend on the specific clinical indication. These are both TNF-alpha Inhibitor agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AMJEVITA is: Subcutaneous injection: 40 mg every other week; for patients with Crohn disease, an initial dose of 160 mg (given as four 40 mg injections in one day or two 40 mg injections per day for two consecutive days) followed by 80 mg at week 2 and 40 mg every other week starting at week 4.. The standard adult dose of ERELZI is: For plaque psoriasis: 100 mg subcutaneous injection once weekly, after initial loading dose of 200 mg at weeks 0, 1, 2, 3, and 4. For psoriatic arthritis: 100 mg subcutaneous injection once weekly.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AMJEVITA and ERELZI in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AMJEVITA is classified as Category C. Amjevita (adalimumab) is an IgG1 monoclonal antibody that crosses the placenta during the third trimester, with highest fetal exposure in the third trimester. In the first and seco. ERELZI is classified as Category C. Pregnancy Category N. No adequate animal reproduction studies. No well-controlled human studies. At therapeutic doses, immunomodulatory effects may theoretically increase risk of p. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.